NRD
AVNS

Nebula Research & Development’s Avanos Medical AVNS Stock Holding History

Nebula Research & Development’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,002
Closed -$219K – 933
2024
Q2 		$219K Buy
+11,002
New +$214K 0.04% 703
2023
Q4 		– Sell
-11,298
Closed -$228K – 645
2023
Q3 		$228K Buy
+11,298
New +$256K 0.12% 365

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Nebula Research & Development's AVNS Position: Q3 2024 in Review

Nebula Research & Development sold out of Avanos Medical (AVNS) in Q3 2024, closing a stake of 11,002 shares — an estimated $219K sold.

Nebula Research & Development first reported a position in AVNS in Q3 2023 and held it in 2 quarters. The position peaked at $228K in Q3 2023. 260 funds tracked by Wall St. Rank hold AVNS as of Q3 2024.

  • Nebula Research & Development reported no remaining Avanos Medical position as of Q3 2024 after selling out during the quarter.
  • Nebula Research & Development sold 11,002 Avanos Medical shares in Q3 2024, an estimated $219K.
  • Nebula Research & Development first reported a position in Avanos Medical in Q3 2023 and held it in 2 quarters.
  • Nebula Research & Development's Avanos Medical position peaked at $228K in Q3 2023.
  • 260 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2024.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.